NCT07065383 Rebalancing the Fat Content of the Heart and Muscles
| NCT ID | NCT07065383 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Aberdeen |
| Condition | Diabetes Mellitus Type 2 |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2028-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-08-01 with a primary completion date of 2028-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Traditional diabetes therapies focus on improving blood sugar control. However, many studies show that this may not be enough. New treatments focusing on weight loss have heralded better results. One of these treatments is Semaglutide and the investigators wish to examine its effects further in this study. The investigators propose to investigate what happens to the fat inside the heart and the leg muscles.
Eligibility Criteria
Inclusion Criteria: * Patients with a confirmed diagnosis of type 2 diabetes established in the previous 10 years between the ages of 20 and 75 * HbA1c ≥ 53 mmol/mol (7%) typically on diet and/or metformin/sulphonylureas (and/or sodium-glucose cotransporter-2 inhibitors, Dipeptidyl peptidase 4 inhibitors, thiazolidinediones, but not on insulin) * Patients who do not meet the WHO recommendations on physical activity (≤150 minutes per week) of moderate-vigorous physical activity (MVPA) * Patients who have a BMI of ≥27 but with a body weight of less than 140kgs due to limitations of the scanner table weight limit * Current or recent (within 3 months) eGFR \>30 mL/min/1.73m2) * Able to understand written and spoken English Exclusion Criteria: * Any previously unknown cardiac condition other than mild valvular disease * Any history of known coronary artery disease (including myocardial infarction and myocardial infarction with normal coronary arteries) * Any relevant or untreated endocrine condition (i.e. Cushings) * Impaired renal function (defined as estimated glomerular filtration rate of less than 30 mL/min/1.73m2) * Blood pressure of more than 180/100 mmHg * Patients on any other medication known to influence glucose or fatty acids metabolism (niacin, omega-3 fatty acids, other glucagon-like peptide-1 receptor agonists) * Patients with any dietary habits that may interfere with the investigation (for example high fat vegan diets, as we know form prior research that they have very different intramyocellular fat storage compared to those on no dietary preferences) * Patients with any history of any medical or surgical condition that in the judgement of the investigators may interfere with the exercise regime (i.e. peripheral vascular disease, arthritis), fatty acids metabolism (i.e. lipid storage diseases) or may compromise the safety of the participant (i.e. neurological syndromes for whom an intense exercise program could result in musculo-skeletal injury or accidents due to loss of balance). * Patients with a sensitivity to Semaglutide (known hypersensitivity, diabetic retinopathy, pregnancy, history of pancreatitis or history of any cancer) * Significant asthma or pulmonary disease * Participants unable to cycle on the ergometer * Unable to perform exercise testing (e.g. prosthetic limbs) * Pregnancy, breastfeeding or considering pregnancy. * Patients who have recently had gastrointestinal contrast or radionuclides * Inability to lie flat or remain motionless for scanning procedures * Patients whose girth size cannot allow them to fit in the magnetic resonance scanner (there is no set location to measure as this is different for everyone, but we have a plastic hoop that can be fitted around the largest circumference to check the fit) * Subjects who are not able to engage into a physical training regime or feel that they do not have the interest or sustained motivation to follow one. * Participants currently enrolled in other interventional clinical research * Participants not able to understand written or verbal English
Contact & Investigator
Dana Dawson, DM
PRINCIPAL INVESTIGATOR
University of Aberdeen
Frequently Asked Questions
Who can join the NCT07065383 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 75 Years, studying Diabetes Mellitus Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07065383 currently recruiting?
Yes, NCT07065383 is actively recruiting participants. Contact the research team at alexander.davidson@abdn.ac.uk for enrollment information.
Where is the NCT07065383 trial being conducted?
This trial is being conducted at Aberdeen, United Kingdom.
Who is sponsoring the NCT07065383 clinical trial?
NCT07065383 is sponsored by University of Aberdeen. The principal investigator is Dana Dawson, DM at University of Aberdeen. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.